Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.
Nanomedicine (Lond)
; 13(10): 1107-1120, 2018 05.
Article
in En
| MEDLINE
| ID: mdl-29874151
ABSTRACT
AIM:
This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer. MATERIALS &METHODS:
We prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity in vitro and in lung cancer-bearing mice.RESULTS:
Drug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and in vivo without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways.CONCLUSION:
The combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acrylamides
/
Drug Delivery Systems
/
Paclitaxel
/
Carcinoma, Non-Small-Cell Lung
/
Aniline Compounds
Limits:
Animals
/
Humans
Language:
En
Journal:
Nanomedicine (Lond)
Year:
2018
Document type:
Article
Affiliation country:
China